Key Takeaway
MTHFR C677T variants are associated with elevated homocysteine and increased cardiovascular disease risk, supporting the rationale for methylation support in affected individuals.
Summary
This meta-analysis examined the relationship between MTHFR gene variants, homocysteine levels, and cardiovascular disease risk.
Study scope:
- Meta-analysis of multiple studies
- Focused on C677T polymorphism
- Examined homocysteine levels
- Assessed cardiovascular outcomes
Key findings:
- TT genotype (homozygous) associated with 25% higher CVD risk
- Elevated homocysteine levels in variant carriers
- Effect modified by folate status
- Higher risk in low-folate populations
Homocysteine effects by genotype:
| Genotype | Homocysteine | CVD Risk |
|---|---|---|
| CC (normal) | Baseline | Reference |
| CT (heterozygous) | +10-15% | Slight increase |
| TT (homozygous) | +25-30% | ~25% higher |
Folate interaction:
- Adequate folate attenuates risk
- Low folate + TT genotype = highest risk
- Supplementation can normalize homocysteine
- Methylfolate may be more effective than folic acid
Clinical implications:
- MTHFR testing can identify at-risk individuals
- Homocysteine monitoring useful
- Methylated B vitamins can address elevated homocysteine
- Personalized approach based on genetics
Clinical significance:
Provides genetic rationale for methylation support, showing that MTHFR variants have real physiological consequences that can be addressed with appropriate supplementation.